• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Document › Details

AstraZeneca plc. (2/2/18). "Press Release: Full-Year 2017 Results".

	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Product	Brilinta®
	Product 2	Farxiga®
	Person	Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“AstraZeneca’s revenues improved over the course of the year, a sign of how our company is steadily turning a corner. Strong commercial execution helped us bring our science to more patients, making the most of our exciting pipeline. We made encouraging progress across the main therapy areas and delivered strong growth in China.

Alongside our CVMD medicines Brilinta and Farxiga reaching blockbuster status, we launched our first Respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence. As well as bringing five new medicines to patients last year, we continued to find more potential uses for existing treatments, including Lynparza and Tagrisso.

We remain committed to our progressive dividend policy. Our strategy is working, propelled by a strong pipeline, good sales performance and continued cost discipline.”

Downloads

Full-Year 2017 Results announcement (PDF 1.6mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf ]

Full-Year 2017 Results investor presentation (PDF 4.4mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20investor%20presentation.pdf ]

Full-Year 2017 Clinical trials appendix (PDF 1.7mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20Clinical%20trials%20appendix.pdf ]

Record changed: 2018-02-08

Advertisement

More documents for AstraZeneca (Group)

• [1] Horizon Discovery Group plc. (9/14/18). "Press Release: Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca as Part of Its Functional Genomics Discovery Platform". Cambridge....
• [2] Definiens AG. (9/10/18). "Press Release: Definiens Embarks on Digital Pathology Collaboration with Merck's Exploratory and Clinical Development Programs". Munich....
• [3] Congenica Ltd.. (8/28/18). "Press Release: Congenica Appoints Wendy Britten as Chief Financial Officer". Cambridge....
• [4] Pieris Pharmaceuticals, Inc.. (8/9/18). "Press Release: Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update". Boston, MA....
• [5] Definiens AG. (7/26/18). "Press Release: Definiens Strengthens Digital Data and Science Strategy by Appointing Mr. Markus Schunk as Chief Operating Officer". Munich....
• [6] AstraZeneca plc. (6/12/18). "Press Release: Update on Phase III Clinical Trials of Lanabecestat for Alzheimer’s Disease. Independent Data Monitoring Committee Advises Lanabecestat Is Unlikely to Meet Primary Endpoints, Leading to Decision to Discontinue...
• [7] Bicycle Therapeutics Ltd.. (5/24/18). "Press Release: Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca". Cambridge & Boston, MA....
• [8] Innate Pharma S.A.. (5/16/18). "Press Release: First Quarter 2018 Report". Marseille....
• [9] AstraZeneca plc. (5/11/18). "Press Release: AstraZeneca Provides Update on GALATHEA Phase III Trial for Fasenra in Chronic Obstructive Pulmonary Disease"....
• [10] Pieris Pharmaceuticals, Inc.. (5/10/18). "Press Release: Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update". Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2018. Made in Germany.